We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Date
- 2025 (38)
- 2024 (86)
- 2023 (73)
- 2022 (59)
- 2021 (124)
- 2020 (107)
- 2019 (98)
- 2018 (95)
- 2017 (73)
- 2016 (12)
- 2015 (22)
- 2014 (19)
- 2013 (9)
- 2012 (8)
- 2011 (14)
- 2010 (27)
- 2009 (13)
- 2008 (5)
- 2007 (11)
- 2006 (8)
- 2005 (4)
- 2004 (8)
- 2003 (3)
- 2002 (10)
- 2001 (6)
- 2000 (20)
- 1999 (9)
- 1998 (12)
- 1997 (16)
- 1996 (8)
- 1995 (3)
- 1994 (33)
- 1993 (18)
- 1992 (5)
- 1991 (86)
Sponsor content
1142 result(s) found, displaying 71 to 80
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABRYSVO recombinant respiratory syncytial virus pre-fusion F protein 120 microgram/0.5 mL bivalent vaccine powder for injection vial + diluent syringe.
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Australian public assessment report (AusPar)Comirnaty Original/Omicron BA.4-5 Vaccine was provisionally approved for immunisation against coronavirus disease 2019 (COVID-19) caused by SARSCoV-2 in individuals 6 months of age or older.
-
-
Australian public assessment report (AusPar)Velsipity (etrasimod) was approved for the treatment of adults with moderately to severely active ulcerative colitis who have not benefited from prior therapies
-
DBL Adrenaline injection BP (1 in 1000) 1mg/1ml ampoules Cancelled under Section 30(1)(c) of the Act
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd -
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Australian public assessment report (AusPar)Xeljanz (tofacitinib) was approved for the treatment of ankylosing spondylitis and for active polyarticular course juvenile idiopathic arthritis.